References
- Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev [Internet]. 2017;212518. [cited 2021 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/#__ffn_sectitle
- Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation [Internet]. 2019;139. DOI:10.1161/CIR.0000000000000659
- Virani S, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics- 2020 update: a report from the American Heart Association. Circulation. [Internet]. 2020 Jan 29 [cited 2021 Feb 19];141. Available from:. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000757
- Kaplinsky E, Mallarkey G. Cardiac myosin activators for heart failure therapy: focus on omecamtiv Mecarbil. Drugs Context [Internet]. 2018 Apr 23 [cited 2021 Feb 19];7. Available from:. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916097/
- Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activatory in conscious dogs with systolic heart failure. Circulation [Internet]. 2010 May 24 [cited 2021 Feb 18];3. Available from: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.109.930321
- Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure- GALACTIC-HF. American College of Cardiology; 2021. [ Internet]. [cited 2021 Feb 23]. Available from: https://www.acc.org/latest-in-cardiology/clinical-trials/2020/11/11/21/01/galactic-hf.
- Teerlink JR, Diaz R, Felker M, et al. Cardiac myosin activation with omecamtiv Mecarbil in systolic heart failure. N Engl J Med Internet. 2021 Jan 14 [ Updated 2021 Feb 18; cited 20 Feb 2021];384:105–116. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2025797
- Patel PH, Nguyen M, Udeani G, et al. Omecamtiv Mecarbil: a novel mechanistic and therapeutic approach to chronic heart failure management. Cureus [Internet]. 2021 Dec 21 [cited 2021 Feb 19]. Available from: https://pubmed.ncbi.nlm.nih.gov/33542867/
- Vaduganathan M, Claggett B, Packer M, et al. Natriuretic petides as biomarkers of treatment response in clinical trials of heart failure. JACC Heart Fail. [Internet]. 2018 Jul [cited 2021 Feb 20]. Available from: https://www.sciencedirect.com/science/article/pii/S2213177918301495
- Omecamtiv Mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. [ Online]. [ cited Feb 21 2021]. Available from: https://www.sciencedirect.com/science/article/pii/S2213177920300020#bib27
- Greenberg B, Chou W, Saikali KG, et al. Safety and tolerability of Omecamtiv Mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan [ cited Feb 22 2021];3:22–29. Available from: https://www.sciencedirect.com/science/article/pii/S2213177914003795
- GALACTIC-HF. Does treatment with omecamtiv Mecarbil improved outcomes in patients with systolic HF? American College of Cardiology; 2020 [ Website]. [cited 2021 Feb 23]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/11/12/20/28/fri-1135am-galactic-hf-aha-2020